<DOC>
	<DOC>NCT01511133</DOC>
	<brief_summary>This study aims to test the clinical samples (stool and serum) previously collected during clinical development of HRV vaccine, to identify if there is any evidence of PCV-1 replication and/or immune response to the PCV-1 in vaccinated infants.</brief_summary>
	<brief_title>Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™</brief_title>
	<detailed_description>Serum and stool samples collected from 4 clinical trials previously conducted for HRV vaccine (Rotarix™) are used in this study.</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<criteria>Inclusion criteria: Subjects enrolled previously in randomized, doubleblind and placebocontrolled studies 444563/022 (NCT00263666), 444563/033 (NCT00757770), 103477 (NCT00169455), and 104480 (NCT00137930); Infants aged 6 to 12 weeks at Dose 1 vaccinated with either HRV vaccine or placebo; Infants for whom sufficient residual volume of the stool samples at predetermined time points is available; Infants for whom sufficient residual volume of the pre and post vaccination blood samples is available. Exclusion criteria: Not applicable</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Laboratory evaluations</keyword>
	<keyword>infants</keyword>
	<keyword>Porcine circovirus type 1 (PCV-1)</keyword>
	<keyword>serologic response</keyword>
	<keyword>human rotavirus (HRV) vaccine</keyword>
</DOC>